A Randomized, Open-Label, Parallel-Group Clinical Study to Evaluate the Efficacy and Safety of Omalizumab in the Treatment of Persistent Moderate and Severe Allergic Asthma and Persistent Allergic Rhinitis in Pediatric Patients 6 to 17 Years of Age

Journal of Allergy and Clinical Immunology - United States

doi 10.1016/j.jaci.2018.12.288